Femasys (FEMY) Stock Price, News & Analysis

Company Overview

Femasys, Inc. is a medical device company dedicated to the design, development and commercialization of minimally invasive diagnostic and therapeutic products for women’s reproductive health. Headquartered in Irvine, California, the company is listed on the NASDAQ under the ticker FEMY and focuses on single‐use catheter technologies that enhance procedure accuracy and patient comfort in fertility care.

Its flagship offerings include the FemVue™ catheter system for non‐radiation fallopian tube patency assessment and the FEMME™ embryo transfer catheter, both engineered with proprietary designs and radiopaque markers. These devices address key challenges in assisted reproductive technology by streamlining workflows, reducing patient discomfort and improving clinical outcomes in infertility clinics and hospitals.

Founded in 2012, Femasys serves markets across North America, Europe, Asia-Pacific and select emerging regions. The company has secured CE Mark approval in Europe and is actively pursuing regulatory clearances in the United States and China. Femasys leverages a combination of direct sales and distributor partnerships to expand its global footprint in the rapidly growing fertility device market.

Under the guidance of an experienced executive team, Femasys is advancing a pipeline of next‐generation catheter systems for enhanced uterine and tubal imaging. The company’s board of directors brings deep expertise in healthcare innovation, regulatory strategy and commercial expansion, positioning Femasys to broaden its product portfolio and scale operations worldwide.

Key Stats

• Today's Range: $0.90 to $0.98
• 50-Day Range: $0.80 to $1.18
• 52-Week Range: $0.69 to $1.80
• Volume: 200,231 shs
• Average Volume: 265,840 shs
• Market Capitalization: $30.08 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $8.67
• Consensus Rating: Buy

Femasys Stock Analysis - MarketRank™

Femasys scored higher than 58% of companies evaluated by MarketBeat, and ranked 465th out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Femasys has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Femasys has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Femasys are expected to grow in the coming year, from ($0.86) to ($0.59) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Femasys is -1.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Femasys is -1.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Femasys has a P/B Ratio of 9.25. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.77% of the float of Femasys has been sold short.

Short Interest Ratio / Days to Cover

Femasys has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Femasys has recently increased by 19.53%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Femasys does not currently pay a dividend.

Dividend Growth

Femasys does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.77% of the float of Femasys has been sold short.

Short Interest Ratio / Days to Cover

Femasys has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Femasys has recently increased by 19.53%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: 0.93

News Sentiment

Femasys has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Femasys this week, compared to 1 article on an average week.

Search Interest

Only 2 people have searched for FEMY on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Femasys to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Femasys insiders have not sold or bought any company stock.

Percentage Held by Insiders

11.54% of the stock of Femasys is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

65.27% of the stock of Femasys is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

FEMY Stock Analysis - Frequently Asked Questions

How have FEMY shares performed this year?

Femasys' stock was trading at $1.10 at the beginning of the year. Since then, FEMY stock has decreased by 15.9% and is now trading at $0.9248.

How were Femasys' earnings last quarter?

Femasys Inc. (NASDAQ:FEMY) posted its earnings results on Thursday, May, 8th. The company reported ($0.23) EPS for the quarter, missing analysts' consensus estimates of ($0.17) by $0.06. The company had revenue of $0.34 million for the quarter, compared to analysts' expectations of $1.14 million. Femasys had a negative net margin of 1,242.06% and a negative trailing twelve-month return on equity of 392.45%.

When did Femasys IPO?

Femasys (FEMY) raised $35 million in an IPO on Friday, June 18th 2021. The company issued 2,700,000 shares at $12.00-$14.00 per share. Chardan and JonesTrading acted as the underwriters for the IPO.

How do I buy shares of Femasys?

Shares of FEMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Femasys own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Femasys investors own include Sangamo Therapeutics (SGMO), Aurora Cannabis (ACB), Canoo (GOEV), FuelCell Energy (FCEL), Agenus (AGEN), Geron (GERN) and Eos Energy Enterprises (EOSE).

Company Calendar

• Last Earnings: 5/08/2025
• Today: 7/13/2025
• Next Earnings (Estimated): 8/14/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:FEMY
• CIK: 1339005
• Web: www.femasys.com
• Phone: 770-500-3910
• Fax: N/A
• Employees: 30
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Femasys: $8.67
• High Price Target: $12.00
• Low Price Target: $6.00
• Potential Upside/Downside: +837.1%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.91)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$18.82 million
• Net Margins: -1,242.06%
• Pretax Margin: -1,241.65%
• Return on Equity: -392.45%
• Return on Assets: -137.15%

Debt

• Debt-to-Equity Ratio: 0.02
• Current Ratio: 0.93
• Quick Ratio: 0.54

Sales & Book Value

• Annual Sales: $1.63 million
• Price / Sales: 18.46
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.10 per share
• Price / Book: 9.25

Miscellaneous

• Outstanding Shares: 32,530,000
• Free Float: 28,772,000
• Market Cap: $30.08 million
• Optionable: Not Optionable
• Beta: -2.56